All In Biotech

Drug Trial Radar · NCT07663903

Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment

A Single-arm, Open-label, Multicenter Phase III Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-demand Treatment in Patients With Severe Hemophilia A (Adults and Adolescents) .

Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Apr 14, 2026

Primary completion

Feb 2027

Study completion Jun 2027

Sponsor

Sponsor type
Industry
First posted
Jun 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The indication for this product is to control bleeding in patients with hemophilia A (congenital deficiency of factor VIII). The primary objective: Evaluation of the efficacy of recombinant human coagulation factor VIII-Fc fusion protein for injection (FRSW107) as an on-demand treatment in previously treated patients with severe hemophilia A. Secondary objectives: Evaluation of the safety and immunogenicity of FRSW107 as an on-demand therapy in previously treated patients with severe hemophilia A. Evaluate the on-demand treatment's PK profile of FRSW107 in previously treated patients with severe hemophilia A based on population pharmacokinetic (PopPK) methods ; preliminarily investigate the exposure-response (E-R) relationship of FRSW107 on-demand treatment in these patients if data permit.

Conditions

  • Severe Hemophilia A

Interventions

  • FRSW107Drug

    Treatment for 6 months as needed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The haemostatic effective rateTime frame: 6 months

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Fuyang Hospital, Affiliated to Anhui Medical University

    Fuyang, China

  • Fujian Medical University Union Hospital

    Fuzhou, China

  • Ganzhou People's Hospital

    Ganzhou, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, China

  • Anhui Provincial Hospital

    Hefei, China

  • Huai'an Second People's Hospital

    Huai'an, China

  • Jinan central hospital

    Jinan, China

  • The Second Affiliated Hospital of Kunming Medical University

    Kunming, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, China

  • Affiliated Hospital of Nantong University

    Nantong, China

  • The First Affiliated Hospital of Nanyang Medical College

    Nanyang, China

  • Qinghai Provincial People's Hospital

    Qinghai, China

  • Rizhao People's Hospital

    Rizhao, China

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, China

  • The Second Hospital of Shanxi Medical University

    Taiyuan, China

  • North China University of Science and Technology Affiliated Hospital

    Tangshan, China

  • Wenzhou People's Hospital

    Wenzhou, China

  • Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology.

    Wuhan, China

  • Affiliated Hospital of Jiangnan University

    Wuxi, China

  • Xi'an Central Hospital

    Xi'an, China

  • Subei People's Hospital of Jiangsu province

    Yangzhou, China

  • Henan Cancer Hospital

    Zhengzhou, China

  • Zhengzhou People's Hospital

    Zhengzhou, China

  • Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.